Back to top
more

Ethos Technologies Inc. (LIFE)

(Real Time Quote from BATS)

$39.21 USD

39.21
369,100

+0.10 (0.26%)

Updated Aug 27, 2026 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (205 out of 247)

Industry: Insurance - Life Insurance

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

by Zacks Equity Research

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

Zacks Equity Research

Are Options Traders Betting on a Big Move in aTyr Pharma (LIFE) Stock?

by Zacks Equity Research

Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -39.13% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Atyr Pharma (LIFE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Atyr Pharma (LIFE) Moves 26.3% Higher: Will This Strength Last?

by Zacks Equity Research

Atyr Pharma (LIFE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Atyr Pharma (LIFE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.